retatrutide
Retatrutide vs Tirzepatide vs Semaglutide for Research Use
Retatrutide vs tirzepatide vs semaglutide for research use compared by receptor target, molecular structure, and how listings present each compound's specs.
Medically reviewed by Thomas Kline, PhD, biochemist — Last reviewed
Thomas Kline, PhD is a biochemist with a doctorate in structural biochemistry from MIT and 16 years of research in GLP receptor biology and synthetic peptide analog pharmacology.
Retatrutide vs tirzepatide vs semaglutide for research use comes down to one structural variable: how many receptor targets each peptide’s sequence is built to engage. Semaglutide is a single-target GLP-1 receptor agonist, tirzepatide is a dual-target GLP-1/GIP agonist, and retatrutide is a triple-target agonist that adds glucagon receptor activity on top of the other two. Everything else a listing states — molecular weight, sequence length, storage guidance — follows from that underlying receptor count.
The Core Structural Difference
Each of these three peptides is built around the GLP-1 receptor, but they diverge in what else their sequence is designed to bind. Semaglutide’s structure targets GLP-1 receptors only. Tirzepatide’s sequence is engineered to activate both GLP-1 and GIP receptors, which is why it is classified as a dual agonist rather than a single-target compound. Retatrutide extends that pattern one step further, with a sequence built to activate GLP-1, GIP, and glucagon receptors together, making it a triple agonist.
This progression is cumulative rather than a ranking of strength. A triple agonist is not simply a “stronger” version of a single agonist — it is a peptide with a broader binding profile, engaging three distinct receptor pathways instead of one. Listings that state receptor targets explicitly, rather than relying on the single/dual/triple label alone, give a more complete picture of what a given vial’s contents are built to do at the molecular level.
Molecular Weight and Sequence Length
Because retatrutide, tirzepatide, and semaglutide differ in how many receptors they target, they also differ in sequence composition and molecular weight, figures that appear on most spec sheets and certificates of analysis. A longer, more complex sequence generally corresponds to a higher molecular weight, and researchers comparing vials across suppliers often cross-check this figure against the peptide’s stated identity as a first pass at verifying listing accuracy.
| Compound | Receptor targets | Agonist classification |
|---|---|---|
| Semaglutide | GLP-1 | Single |
| Tirzepatide | GLP-1, GIP | Dual |
| Retatrutide | GLP-1, GIP, glucagon | Triple |
The table above reflects classification and receptor identity only. It does not represent a ranking of effect, since receptor count describes binding breadth, not intensity.
How Listings Present Reconstitution Figures
Reconstitution math is identical in method across all three compounds, even though the peptides themselves differ structurally. A listing’s concentration figure is always vial mass in milligrams divided by the volume of bacteriostatic water added, and that relationship holds regardless of which of the three peptides is in the vial.
As a worked example: a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 5 mg ÷ 2 mL = 2.5 mg/mL. Converting that to micrograms, since 1 mg equals 1000 mcg, gives 2500 mcg/mL. On a U-100 insulin syringe, where 1 mL corresponds to 100 unit markings, each unit drawn represents 1/100 of that 2 mL volume, or 25 mcg per unit at this concentration. Checking the arithmetic a second way confirms it: 100 units × 25 mcg/unit = 2500 mcg, which matches the total mcg/mL figure calculated above.
That worked figure is specific to a 5 mg vial and 2 mL of diluent. A different vial size or a different diluent volume changes the concentration proportionally, so the same two-step method — divide for concentration, then convert units — applies regardless of which of the three compounds a listing describes. Readers working through their own reconstitution figures can cross-check the arithmetic against a dedicated calculator such as peptcalc.com rather than relying on mental math alone.
Why Listings Group These Three Together
Semaglutide, tirzepatide, and retatrutide are grouped together in comparison listings because they represent successive steps along the same receptor-target progression, not because they are interchangeable. A listing that presents all three side by side is typically doing so to illustrate how the classification scheme scales, from one target to three, rather than suggesting the compounds are equivalent at different strengths.
This grouping convention shows up across the broader catalogue as well. A side-by-side breakdown of retatrutide against the other two compounds lines up all three by receptor target and classification in the same structural terms used here, which is a useful cross-check when a listing’s own comparison table is sparse on specifics. Readers looking for the same receptor-target framework applied to a wider set of GLP-1 family compounds can also find it laid out at glp3rt.net, which organizes its reference material around this same single/dual/triple structure.
Storage and Handling Notes Across the Three
Storage guidance for all three compounds follows the same general pattern found on most peptide spec sheets: lyophilized vials are typically listed as stable at refrigerated or frozen temperatures prior to reconstitution, while reconstituted solutions carry a shorter stated shelf life and call for refrigeration. None of the three compounds’ receptor-target differences change this storage logic — the guidance is a function of the peptide being in solution, not of which receptors it targets.
Where listings do differ is in how precisely they document these figures. A well-documented listing states lyophilized and reconstituted storage conditions separately, rather than giving one blanket temperature range for both states, since the two states are not chemically equivalent to store.
Reading a Comparison Listing Critically
When a listing places retatrutide, tirzepatide, and semaglutide side by side, the most useful comparison points are the ones that follow directly from receptor target: classification word, named receptors, sequence length, and molecular weight. Figures that do not follow from the structural difference between the three compounds, such as claims about outcomes or relative strength, are not part of what a receptor-target comparison can actually establish and are worth treating with more scrutiny than the structural data.
Cross-referencing the classification word against the named receptor targets is a fast internal-consistency check. A listing that calls retatrutide a “triple agonist” but names only two receptors, for instance, has an inconsistency worth resolving before treating the rest of its spec sheet as reliable.
Summary
Retatrutide vs tirzepatide vs semaglutide for research use is fundamentally a comparison of receptor-target count: one, two, and three receptors respectively, building on the same GLP-1 foundation. That structural difference is what drives the molecular weight, sequence length, and classification language that listings use to describe each compound, while reconstitution method and storage logic remain consistent across all three.